This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Educational Foundation Kyushu Bunka Gakuen, Kaneka Corporation, National University Corporation Kumamoto University. Active years: 2026.
Company Filing History:
1 out of 2 
1 out of 1,762 
1 out of 9 Years Active: 2026
Title: Mitsuharu Ueda: Innovator in Transthyretin Amyloidosis Treatment
Introduction
Mitsuharu Ueda is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of transthyretin amyloidosis. His innovative work has led to the development of a unique stabilizing agent that plays a crucial role in managing this condition.
Latest Patents
Ueda holds a patent for a transthyretin tetramer stabilizing agent, which serves as a preventing agent or progression suppressing agent for transthyretin amyloidosis. This invention includes glabridin, glabrene, and glabrol as key components. The patent emphasizes the importance of these compounds in stabilizing the transthyretin tetramer, thereby offering a potential therapeutic approach to combat the disease.
Career Highlights
Throughout his career, Mitsuharu Ueda has worked with prominent organizations, including Kaneka Corporation and Educational Foundation Kyushu Bunka Gakuen. His experience in these institutions has allowed him to collaborate with other experts in the field and further his research endeavors.
Collaborations
Ueda has collaborated with notable colleagues such as Jinko Sawashita and Yukio Ando. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Mitsuharu Ueda's contributions to the field of transthyretin amyloidosis treatment highlight his innovative spirit and dedication to medical research. His work continues to inspire advancements in therapeutic solutions for this challenging condition.